Pilot Study to Evaluate a Noninvasive Electrocardiographic Monitoring Strategy Associated With Early Discharge in Patients With Conduction Disorders Following TAVI Implantation (IMPROVE Study)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Hospital Universitari Vall d'Hebron Research Institute
- Trial code
- NCT07456280
- Record updated
- 22 July 2026
- Original description
Study to evaluate the efficacy and safety of a non-invasive electrocardiographic monitoring strategy associated with early discharge in patients with conduction disorder after transfemoral TAVI implantation, and its potential benefits compared to standard care.Read full original descriptionShow less
Study to evaluate the efficacy and safety of a non-invasive electrocardiographic monitoring strategy associated with early discharge in patients with conduction disorder after transfemoral TAVI implantation, and its potential benefits compared to standard care.
Inclusion: All inclusion criteria must be met; Age ≥ 18 years and; Undergone successful transfemoral or transaortic TAVI for severe aortic stenosis and; Presence of at least one of the following conduction disorders and; Pre-procedural basal conduction disorder (e.g., right/left bundle branch block, bifascicular block, IVCD) with QRS between 120-160 msec; De novo conduction disorder after TAVI (de novo bundle branch block) with QRS between 120-160 msec; Clinical stability at 24 hours post-procedure and; Capacity to give informed consent.
Exclusion: Haemodynamic instability or complications of TAVI (major bleeding, stroke, decompensated heart failure) that contraindicate early discharge; No exclusion criteria must be met; Immediate indication for permanent pacemaker following the procedure; Persistent complete atrioventricular block; QRS >160 msec and/or PR prolongation; Technical or clinical impossibility of using the PhysioMem PM 1004G monitoring system; Life expectancy < 12 months due to non-cardiovascular comorbidity; Refusal or inability to undergo outpatient follow-up; Pregnant or breastfeeding.